WilmerHale Advises Autobahn Labs in Drug Discovery Collaboration with UCSF

WilmerHale Advises Autobahn Labs in Drug Discovery Collaboration with UCSF

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On December 21, 2020, Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. The collaboration with UCSF is the second partnership announced by Autobahn Labs since the organization’s launch in June 2020, and expands the reach of the innovative partnership between Samsara BioCapital and Evotec.

The WilmerHale team representing Autobahn Labs includes Jason Kropp, Jenna Ventorino and Ryan Crane.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel